In this study, 50 DKA patients admitted in our hospital from May 2017 to May 2020 are included as the subjectsin this study, and they are divided into the Insulin Lispro group and the Insulin Aspart group. It is shown that there is no significant difference in the recovering time of the blood glucose, and the complication rates between the two groups (P>0.05); in the Lispro group, the fasting blood glucose and the postprandial 2 h blood glucose levels are lower than those in the Aspart group, and the recovery times of the negative urinary ketone and the bloody pH value are shorter than those in the Aspart group. It is suggested that the insulin Lispro has certain advantages in the treatment of the DKA, with higher speeds of controlling the blood glucose and correcting the DKA.

diabetic ketoacidosis  /  insulin Lispro  /  insulin Aspart  /  efficacy evaluation  /  safety evaluation